Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model.
OBJECTIVE
Hematogenous spread of bacillus Calmette-Guerin (BCG) after intravesical instillation for bladder cancer is rare but it may result in systemic infection and hypersensitivity reaction. We investigated fluoroquinolones and steroids in an animal model to improve the therapeutic options in local and systemic BCG infection. Furthermore, the antitumor effectiveness of intravesical BCG with simultaneous application of fluoroquinolones and/or steroids was tested.


METHODS
Oral antimicrobial therapy with and without steroids was started immediately after intraperitoneal injection using fluoroquinolones or trimethoprim-sulfamethoxazole. To evaluate the therapeutic options against a hyperergic reaction after repeat systemic BCG infection re-challenge was performed with intraperitoneal BCG 7 days after primary infection and oral therapy was given with fluoroquinolones or trimethoprim-sulfamethoxazole with and without steroids. The influence of continuous oral fluoroquinolone therapy on the antitumor effect of BCG was also tested in the MB 49 orthotopic murine bladder tumor model.


RESULTS
After primary systemic infection fluoroquinolone therapy alone led to significantly prolonged survival in mice (log rank test p = 0.041), whereas trimethoprim-sulfamethoxazole was ineffective. There was no additional effect of steroid administration. Steroids alone led to premature death (log rank test p = 0.022). After secondary BCG infection only steroid treated animals had prolonged survival (log rank test p = 0.032), whereas antimicrobials alone had no effect. The therapeutic efficacy of BCG in the orthotopic bladder tumor model was not affected by continuous oral fluoroquinolones in terms of survival (log rank test p = 0.001) or bladder weight (Wilcoxon test p = 0.001) compared with untreated controls.


CONCLUSIONS
In a mouse model fluoroquinolones had a beneficial effect for primary systemic BCG infections, whereas the hyperergic reaction after repeat BCG infection was susceptible only to steroids. Administering fluoroquinolones during an intravesical treatment course does not affect the antitumor efficacy of BCG.
Durek
C
C
Department of Urology, Medical University of Lübeck, Lübeck, Germany.
Jurczok
A
A
Werner
H
H
Jocham
D
D
Bohle
A
A
D000818:Animals; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002939:Ciprofloxacin / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D051379:Mice; D008810:Mice, Inbred C57BL; D009163:Mycobacterium bovis / Q000187:drug effects* / Q000472:pathogenicity; D015242:Ofloxacin / Q000494:pharmacology*; D011239:Prednisolone / Q000494:pharmacology*; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology*; D014376:Tuberculosis / Q000382:microbiology*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000382:microbiology; D001749:Urinary Bladder Neoplasms / Q000382:microbiology; D014774:Virulence
D002939:Ciprofloxacin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D011239:Prednisolone; D015242:Ofloxacin